{"id":"ang-3070","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Gastrointestinal disorders"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"ANG-3070 inhibits TEK (TIE2) receptor signaling, which is involved in vascular endothelial growth and stabilization. By modulating angiopoietin-TEK pathway activity, the drug aims to restore vascular function and promote tissue healing in ischemic conditions. This mechanism is particularly relevant for improving perfusion and reducing inflammation in tissues with compromised blood supply.","oneSentence":"ANG-3070 is a tyrosine kinase inhibitor that targets angiopoietin signaling to promote vascular stabilization and tissue repair.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:56:35.729Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic kidney disease"},{"name":"Peripheral artery disease"}]},"trialDetails":[{"nctId":"NCT05387785","phase":"PHASE1","title":"Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis","status":"UNKNOWN","sponsor":"Angion Biomedica Corp","startDate":"2022-06","conditions":"Idiopathic Pulmonary Fibrosis (IPF)","enrollment":20},{"nctId":"NCT04939116","phase":"PHASE2","title":"Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease","status":"UNKNOWN","sponsor":"Angion Biomedica Corp","startDate":"2021-12-24","conditions":"Glomerular Disease, Proteinuria","enrollment":100},{"nctId":"NCT04196179","phase":"PHASE1","title":"ANG-3070 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Angion Biomedica Corp","startDate":"2019-12-17","conditions":"Healthy Volunteers","enrollment":97}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ANG-3070","genericName":"ANG-3070","companyName":"Angion Biomedica Corp","companyId":"angion-biomedica-corp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ANG-3070 is a tyrosine kinase inhibitor that targets angiopoietin signaling to promote vascular stabilization and tissue repair. Used for Diabetic kidney disease, Peripheral artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}